Logo image of JSPR

JASPER THERAPEUTICS INC (JSPR) Stock Fundamental Analysis

NASDAQ:JSPR - Nasdaq - US4718712023 - Common Stock - Currency: USD

6.54  +0.22 (+3.48%)

Fundamental Rating

2

JSPR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While JSPR has a great health rating, there are worries on its profitability. JSPR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year JSPR has reported negative net income.
JSPR had a negative operating cash flow in the past year.
JSPR had negative earnings in each of the past 5 years.
In the past 5 years JSPR always reported negative operating cash flow.
JSPR Yearly Net Income VS EBIT VS OCF VS FCFJSPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -63.90%, JSPR is not doing good in the industry: 62.30% of the companies in the same industry are doing better.
JSPR has a Return On Equity (-75.92%) which is in line with its industry peers.
Industry RankSector Rank
ROA -63.9%
ROE -75.92%
ROIC N/A
ROA(3y)-59.52%
ROA(5y)-66.5%
ROE(3y)-76.99%
ROE(5y)-123.64%
ROIC(3y)N/A
ROIC(5y)N/A
JSPR Yearly ROA, ROE, ROICJSPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for JSPR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JSPR Yearly Profit, Operating, Gross MarginsJSPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, JSPR has more shares outstanding
JSPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
JSPR Yearly Shares OutstandingJSPR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
JSPR Yearly Total Debt VS Total AssetsJSPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -0.72, we must say that JSPR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.72, JSPR perfoms like the industry average, outperforming 59.82% of the companies in the same industry.
JSPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.72
ROIC/WACCN/A
WACCN/A
JSPR Yearly LT Debt VS Equity VS FCFJSPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M

2.3 Liquidity

JSPR has a Current Ratio of 7.61. This indicates that JSPR is financially healthy and has no problem in meeting its short term obligations.
JSPR has a Current ratio of 7.61. This is in the better half of the industry: JSPR outperforms 70.80% of its industry peers.
A Quick Ratio of 7.61 indicates that JSPR has no problem at all paying its short term obligations.
JSPR's Quick ratio of 7.61 is fine compared to the rest of the industry. JSPR outperforms 70.80% of its industry peers.
Industry RankSector Rank
Current Ratio 7.61
Quick Ratio 7.61
JSPR Yearly Current Assets VS Current LiabilitesJSPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

0

3. Growth

3.1 Past

JSPR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.89%, which is quite impressive.
EPS 1Y (TTM)42.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -11.79% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y24.88%
EPS Next 2Y11.72%
EPS Next 3Y4.96%
EPS Next 5Y-11.79%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JSPR Yearly Revenue VS EstimatesJSPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
JSPR Yearly EPS VS EstimatesJSPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for JSPR. In the last year negative earnings were reported.
Also next year JSPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JSPR Price Earnings VS Forward Price EarningsJSPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JSPR Per share dataJSPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.72%
EPS Next 3Y4.96%

More info and screens

0

5. Dividend

5.1 Amount

JSPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JASPER THERAPEUTICS INC

NASDAQ:JSPR (2/5/2025, 10:28:17 AM)

6.54

+0.22 (+3.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners97.69%
Inst Owner Change-0.1%
Ins Owners1.27%
Ins Owner Change0%
Market Cap98.10M
Analysts85.88
Price Target65.03 (894.34%)
Short Float %21.71%
Short Ratio6.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.4%
Min EPS beat(2)-13.47%
Max EPS beat(2)12.67%
EPS beat(4)3
Avg EPS beat(4)6.42%
Min EPS beat(4)-13.47%
Max EPS beat(4)17.57%
EPS beat(8)6
Avg EPS beat(8)3.98%
EPS beat(12)9
Avg EPS beat(12)0.6%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.46%
PT rev (3m)-10.99%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)-3.65%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.17
P/tB 1.17
EV/EBITDA N/A
EPS(TTM)-4.74
EYN/A
EPS(NY)-4.66
Fwd EYN/A
FCF(TTM)-3.91
FCFYN/A
OCF(TTM)-3.86
OCFYN/A
SpS0
BVpS5.58
TBVpS5.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.9%
ROE -75.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.52%
ROA(5y)-66.5%
ROE(3y)-76.99%
ROE(5y)-123.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.62%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.61
Quick Ratio 7.61
Altman-Z -0.72
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)242.4%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.5%
EPS Next Y24.88%
EPS Next 2Y11.72%
EPS Next 3Y4.96%
EPS Next 5Y-11.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.24%
OCF growth 3YN/A
OCF growth 5YN/A